title: Antituberculosis therapy and imatinib for chronic myeloid leukemia.
authors.forename: Federica
authors.initials: F
authors.lastname: Sorà
authors.forename: Silvia
authors.initials: S
authors.lastname: De Matteis
authors.forename: Antonella
authors.initials: A
authors.lastname: Di Mario
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Maiuro
authors.forename: Luca
authors.initials: L
authors.lastname: Laurenti
authors.forename: Patrizia
authors.initials: P
authors.lastname: Chiusolo
authors.forename: Fausta
authors.initials: F
authors.lastname: Ardito
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Leone
authors.forename: Simona
authors.initials: S
authors.lastname: Sica
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000627:therapeutic use; D001549:Benzamides; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008875:Middle Aged; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D000995:Antitubercular Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate